Clinical trials: Safety Study
Congenital Heart Disease
Study to Assess Safety of the Pulmonary Valved Conduit (PV-001) in Subjects Undergoing Right Ventricular Outflow Tract Reconstruction
The study is a prospective, non-randomised, open label clinical study to assess the safety of the Bioabsorbable Pulmonary Valved (PV) conduit (PV-001) in subjects > 2 years and < 22 years of age, undergoing Right Ventricular…
- Trial name
- NCT02700100
- Testing
- Bioabsorbable Pulmonary Valved Conduit (PV-001)
- Where
- 3 sites in Hungary, Malaysia and 1 more
- Volunteers
- 12 people
- Sponsor
- Xeltis
Cerebral Venous Thrombosis, Anticoagulants and Thrombotic Disorders
Safety and Efficacy of Edoxaban and Rivaroxaban to Cerebral Venous Thrombosis in Chinese Patients
The goal of this observational study is to learn the safety and efficacy of edoxaban and rivaroxaban in Chinese population with the age range from 18 to 80 years who take edoxaban or rivaroxaban to treat their cerebral venous…
- Conditions
- Cerebral Venous Thrombosis, Anticoagulants and Thrombotic Disorders, Anticoagulation Treatment, Anticoagulant Therapy
- Trial name
- NCT06947707
- Where
- China
- Volunteers
- 1,486 people
- Sponsor
- Xuanwu Hospital, Beijing
Healthy Volunteers With Hyperlipidemia
A First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3 Are Safe and Well Tolerated in Healthy Adults
This study is researching an experimental drug called ALN-ANG3 (called "study drug"). The study is focused on healthy participants with an elevated level of blood lipids (eg, cholesterol and triglycerides).
- Trial name
- NCT06452771
- Testing
- ALN-ANG3
- Where
- New Zealand
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Stable Coronary Artery Disease (CAD), Unstable Angina (Troponin Negative)
Safety of Argatroban Infusion in Conduction Disturbances
To determine change of QTc interval during intravenous argatroban infusion in patients undergoing percutaneous coronary intervention (PCI)
- Trial name
- SAICoDis (NCT05740371)
- Testing
- Argatroban
- Where
- 2 sites in Germany
- Volunteers
- 50 people
- Sponsor
- Tanabe Pharma GmbH
Moderate to Severe Plaque Psoriasis
Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With Psoriasis
Investigate the Safety, Tolerability, Efficacy and pharmacodynamics properties of CT303 in patients with moderate to severe plaque psoriasis
- Trial name
- NCT05258331
- Testing
- CT303
- Where
- 3 sites in South Korea
- Volunteers
- 24 people
- Sponsor
- GC Cell Corporation
Acromegaly
Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
Octreotide capsule is a novel, orally-administered formulation of the commercially-available injectable drug octreotide. In a recent phase 3 trial, oral octreotide capsules demonstrated maintenance of biochemical response up to…
- Trial name
- OPTIMAL (NCT03252353)
- Testing
- octreotide capsules
- Where
- 60 sites in United States, Australia and 15 more
- Volunteers
- 56 people
- Sponsor
- Chiasma, Inc.
Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation
AMG 510 Ethnic Sensitivity Study (CodeBreaK 105).
To evaluate safety, tolerability, PK, and preliminary efficacy of AMG 510 PO QD in subjects of Chinese descent with KRAS p.G12C-mutant advanced/metastatic solid tumors.
- Trial name
- NCT04380753
- Testing
- AMG 510
- Where
- 4 sites in Hong Kong, Taiwan
- Volunteers
- 12 people
- Sponsor
- Amgen
Posttraumatic Stress Disorder
A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2)
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective in people with at least moderate PTSD.
- Trial name
- NCT04077437
- Testing
- Therapy, Midomafetamine
- Where
- 14 sites in United States, Israel
- Volunteers
- 121 people
- Sponsor
- Resilient Pharmaceuticals
Healthy
Pharmacokinetic Interaction and Safety Between NVP-1203-R1 and NVP-1203-R2
The purpose of this study is to compare the pharmacokinetics and safety between NVP-1203-R1 and NVP-1203-R2
- Trial name
- Navipharm (NCT04181437)
- Testing
- NVP-1203-R1, NVP-1203-R2, NVP-1203-R1 and NVP-1203-R2
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- NVP Healthcare
Advanced Malignancy, Advanced Solid Tumors
A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors
This is a Phase 1 dose escalation to assess the safety, tolerability and maximum tolerated dose of subcutaneous administered SDX-7320 in patients with advanced refractory or late-stage solid tumors.
- Conditions
- Advanced Malignancy, Advanced Solid Tumors, Neoplasm, Metastasis
- Trial name
- SDX-0101 (NCT02743637)
- Testing
- SDX-7320
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- SynDevRx, Inc.
No Disease State or Condition
Pain Study to Assess Local Anesthetic Efficacy and Safety of CTY-5339 on Gingival Mucosal Tissue in Normal Volunteers
The purpose of this study is to determine if the topical application to gingival tissue of the combination of benzocaine and tetracaine has a longer duration of local anesthetic activity than benzocaine alone.
- Trial name
- NCT03233737
- Testing
- One spray CTY-5339-A, One spray CTY-5339-CB, One spray CTY-5339-P
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Cetylite Industries
Healthy
A Study of LY3305677 in Healthy Participants
The purpose of this study is to evaluate the safety of LY3305677 and any side effects that might be associated with it. This study will also look at how much LY3305677 gets into the blood stream, how long it takes the body to…
- Trial name
- NCT02972645
- Testing
- LY3305677
- Where
- United Kingdom
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Dumping Syndrome
Phase II Study Evaluating Efficacy, Safety and Pharmacokinetics of Pasireotide in Patients With Dumping Syndrome
multi-center, phase II study evaluating efficacy, safety and pharmacokinetics of pasireotide in patients with dumping syndrome
- Trial name
- NCT01637272
- Testing
- SOM230
- Where
- 17 sites in United States, Belgium and 3 more
- Volunteers
- 43 people
- Sponsor
- Novartis Pharmaceuticals
Migraine
A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-313 in Healthy Participants
This first in-human (FIH) study of UB-313, an anti-calcitonin gene-related peptide based immunotherapeutic candidate, is designed to assess the safety, tolerability, and immunogenicity of 4 selected UB-313 dose regimens in…
- Trial name
- NCT05477095
- Testing
- UB-313
- Where
- Belgium
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Vaxxinity, Inc.
Healthy Participants
The Effect of Education-based Patient Safety on Nursing Leaders' and Educators' Perceptions of Patient Safety Culture in Saudi Arabia
This interventional study is aimed to examine the effect of an education-based patient safety on the perceptions of patient safety culture among nursing leaders and educators in one of the medical cities in Saudi Arabia.
- Trial name
- NCT07095595
- Testing
- Patient Safety Educational Program based on WHO Curriculum
- Where
- Saudi Arabia
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Universiti Putra Malaysia
Dysentery, Dysentery, Shigella
Clinical Trial of the S. Flexneri-S. Sonnei Bivalent Conjugate Vaccine
The goal of this clinical trial is to evaluate the protective efficacy of S. Flexneri-S. Sonnei bivalent conjugate vaccine against diarrhea caused by Shigella infection in infants and children aged 6 months to 5 years.
- Trial name
- NCT06838195
- Testing
- S. Flexneri-S. Sonnei bivalent conjugate vaccine
- Where
- Bangladesh
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Alzheimer's Disease
An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease
The primary purpose of this study is to confirm the clinical efficacy and mechanism of action of GV-971, and identify incidence of known adverse reactions in long-term use and observe new adverse reactions, providing more…
- Trial name
- NCT05908695
- Testing
- GV-971
- Where
- 50 sites in China
- Volunteers
- 1,312 people
- Sponsor
- Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Thyroid Eye Disease
A Safety, Tolerability, and Efficacy Study of Veligrotug (VRDN 001) in Participants With Thyroid Eye Disease (TED)
The investigational drug, veligrotug (VRDN-001), is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R).
- Trial name
- THRIVE (NCT05176639)
- Testing
- Veligrotug
- Where
- 53 sites in United States, Australia and 5 more
- Volunteers
- 113 people
- Sponsor
- Viridian Therapeutics, Inc.
Autism
Study to Evaluate the Efficacy and Safety of Aripiprazole
To evaluate the efficacy of flexibly dosed aripiprazole in reducing serious behavioral problems in Asian children and adolescents with a diagnosis of autism spectrum disorder, as measured by change from baseline to endpoint on…
- Trial name
- NCT02069977
- Testing
- Aripiprazole
- Where
- 6 sites in Philippines, South Korea and 1 more
- Volunteers
- 79 people
- Sponsor
- Yoo-Sook Joung
SARS-CoV2 Infection
Efficacy, Safety and Immunogenicity Study of SARS-CoV-2 Inactivated Vaccine
This phase III trial aims to assess the efficacy, safety and immunogenicity of SARS-CoV-2 Vaccine (inactivated) and lot-to-lot consistency evaluation
- Trial name
- COVID-19 (NCT04508075)
- Testing
- SARS-CoV-2 vaccine (inactivated)
- Where
- Indonesia
- Volunteers
- 1,620 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma